{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-24-000233","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2024-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.339882+00:00","generated_at":"2026-05-29T23:07:04.514045+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Denali Therapeutics amends bylaws for universal proxy and Delaware law updates","bullets":["Board approved amended restated bylaws effective November 12, 2024.","Updates advance notice procedures for director nominations and stockholder proposals.","Requires stockholder to show Rule 14a-19 compliance 5 business days before meeting.","Conforms provisions to current Delaware General Corporation Law.","Updates provisions on directors, board committees, officers, and ministerial changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-24-000233","json":"https://secwatch.observer/filing/0001714899-24-000233.json","markdown":"https://secwatch.observer/filing/0001714899-24-000233.md","text":"https://secwatch.observer/filing/0001714899-24-000233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000233/0001714899-24-000233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000233/dnli-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:07:04.514045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}